Mehdi Touat
YOU?
Author Swipe
View article: IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial Open
TGR shows emerging utility as a quantitative measure for assessing treatment efficacy in glioma. We evaluated three distinct TGR models using volumetric data from patients with mIDH1/2 diffuse glioma from the Phase 3 INDIGO trial (NCT04164…
View article: Classification of spatial patterns of lymphocyte infiltration in gliomas from whole slide imaging
Classification of spatial patterns of lymphocyte infiltration in gliomas from whole slide imaging Open
Primary malignant brain tumors are among the most lethal cancers and are associated with poor survival. T cells are crucial components of the immune response against tumors. However, the spatial organization of T cells in brain tumors and …
View article: Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas
Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas Open
View article: P10.21.B DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED: DISTINCT BIOLOGY AND THERAPEUTIC OPPORTUNITIES
P10.21.B DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED: DISTINCT BIOLOGY AND THERAPEUTIC OPPORTUNITIES Open
BACKGROUND Diffuse midline gliomas (DMG) H3 K27-altered are incurable WHO grade 4 gliomas that pose a significant therapeutic challenge in neuro-oncology. The 2021 WHO Classification of CNS Tumors recognizes four subtypes of DMG, yet clini…
View article: JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB
JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB Open
BACKGROUND Grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas are slowly progressive, malignant, incurable brain tumors with poor long-term prognosis. Patients may experience tumor-related symptoms (eg seizures) that impact t…
View article: P12.25.B A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.
P12.25.B A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT. Open
BACKGROUND Glioblastoma (GBM) is a universally deadly disease with dismal prognosis. The O6-methylguanine methyltransferase (MGMT) promoter methylation is both predictive in response to standard chemoradiation, as well as prognosis, and un…
View article: OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL
OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL Open
BACKGROUND In the Phase 3 INDIGO trial (NCT04164901), vorasidenib, an oral, brain-penetrant, dual inhibitor of mutated isocitrate dehydrogenase 1/2 (mIDH1/2), improved progression-free survival (PFS) versus placebo in patients with mIDH1/2…
View article: P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR) Open
BACKGROUND The international randomized placebo-controlled phase III INDIGO trial has shown improved progression free survival (PFS) of the isocitrate dehydrogenase (IDH) inhibitor vorasidenib in IDH-mutant diffuse gliomas that were consid…
View article: P12.59.B CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
P12.59.B CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE Open
BACKGROUND The median overall survival of patients with an IDH-mutant high-grade gliomas (IDHm HGGs), including grade 3 oligodendroglioma (O3), grade 3 and 4 astrocytoma (A3, A4), is well known. While this clinical information is useful at…
View article: P12.26.A PROGNOSIS IMPACT OF PROCARBAZINE AND/OR VINCRISTINE DISCONTINUATION IN FIRST-LINE TREATMENT BY PCV AND RADIOTHERAPY IN WHO GRADE 3 IDH-MUTANT DIFFUSE GLIOMAS
P12.26.A PROGNOSIS IMPACT OF PROCARBAZINE AND/OR VINCRISTINE DISCONTINUATION IN FIRST-LINE TREATMENT BY PCV AND RADIOTHERAPY IN WHO GRADE 3 IDH-MUTANT DIFFUSE GLIOMAS Open
BACKGROUND WHO Grade 3 IDH-mutant diffuse gliomas (oligodendrogliomas (O3) or astrocytomas (A3)) are chemosensitive tumors. A POLA Network study recently showed a significant improvement in overall survival (OS) in patients with O3 treated…
View article: A Specific Methylation Class Identifies BAP1‐Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology
A Specific Methylation Class Identifies BAP1‐Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology Open
Summary Undifferentiated cytokeratin‐expressing non rhabdoid meningeal tumor can correspond to BAP1 ‐deficient meningiomas. DNA methylation profiling identifies a methylation class specific to BAP1 ‐deficient meningioma. BAP1 ‐deficient me…
View article: Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Open
Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict gliobl…
View article: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas Open
Oncogenic alterations in fibroblast growth factor receptor (FGFR)-family proteins occur across cancers, including pediatric gliomas. Our genomic analysis of 11,635 gliomas across ages finds that 5.3% of all gliomas harbor FGFR alterations,…
View article: Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib
Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib Open
Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options and poor prognosis. Epidermal growth factor receptor (EGFR) alterations, including amplifications, mutations, and fusions, are prevalent in GBM and repres…
View article: INDIGO and Beyond: Approaching Vorasidenib With Cautious Optimism
INDIGO and Beyond: Approaching Vorasidenib With Cautious Optimism Open
View article: Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas <i>IDH</i>‐mutant and 1p/19q codeleted: A French POLA network study
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas <i>IDH</i>‐mutant and 1p/19q codeleted: A French POLA network study Open
Background Brain tumors represent one of the main causes of cancer‐related mortality in young patients. Among them, oligodendrogliomas (OG) are adult‐type diffuse gliomas with the best prognosis. Nevertheless, characterization of these tum…
View article: Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study
Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study Open
None.
View article: 10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS
10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS Open
INTRODUCTION The Phase 3 INDIGO study (NCT04164901) evaluated vorasidenib, an oral,brain-penetrant, dual inhibitor of mutated isocitrate dehydrogenase 1/2 (mIDH1/2), in patients with mIDH1/2 diffuse glioma. The primary endpoint of progress…
View article: Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study Open
Objective Intravascular lymphoma is a rare subtype of B‐cell lymphoma characterized by a clonal proliferation restricted to the lumen of small vessels. Over 50% of patients exhibit central nervous system (CNS) involvement, but diagnosis is…
View article: Spectrum of IDH-mutant tumors in Ollier-Maffucci disease: the triple interaction theory
Spectrum of IDH-mutant tumors in Ollier-Maffucci disease: the triple interaction theory Open
We propose to refine our understanding of the pathophysiology underlying the tumor spectrum observed in patients with Ollier disease (OD) and Maffucci syndrome (MS). On one hand, assuming that all IDH-mutated tumors (as well as enchondroma…
View article: Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1 Open
The standard of care for adult patients with gliomas, glioneuronal, and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a major part of the standard tr…
View article: A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas
A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas Open
Alterations in Fibroblast growth factor receptor (FGFR)-family proteins frequently occur as oncogenes in many cancers, including a subset of pediatric gliomas. Here, we performed a genomic analysis of 11,635 gliomas across ages and found t…
View article: Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors Open
Background With the significant shift in the classification, risk stratification, and standards of care for gliomas, we sought to understand how the overall survival of patients with these tumors is impacted by molecular features, clinical…
View article: Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation
Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation Open
View article: A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients Open
Background The frequency and significance of IDH mutations in glioma across age groups are incompletely understood. We performed a multi-center retrospective age-stratified comparison of patients with IDH-mutant gliomas to identify age-spe…
View article: Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with<i>IDH</i>-Mutant Glioma
Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with<i>IDH</i>-Mutant Glioma Open
Our results, acquired in a clinic setting, confirmed that edited MR spectroscopy is highly specific for both IDH-mutation and 1p/19q-codeletion predictions and can provide a faster prognosis stratification. In the upcoming IDH-inhib…
View article: The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Open
The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments ma…
View article: Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments
Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments Open
Non-Hodgkin lymphomas (NHL) commonly occur in immune-deficient (ID) patients, both HIV-infected and transplanted, and are often EBV-driven with cerebral localization, raising the question of tumor immunogenicity, a critical issue for treat…
View article: A.6 INDIGO: a global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with grade 2 glioma with an IDH1/2 mutation (mIDH1/2)
A.6 INDIGO: a global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with grade 2 glioma with an IDH1/2 mutation (mIDH1/2) Open
Background: We evaluated vorasidenib (VOR), a dual inhibitor of mIDH1/2, in patients with mIDH1/2 glioma (Phase 3; NCT04164901). Methods: Patients with residual/recurrent grade 2 mIDH1/2 oligodendroglioma or astrocytoma were enrolled (age …
View article: Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma Open